Alembic Pharma Gets US FDA Approval For Generic Remodulin Injection

Alembic Pharma Gets US FDA Approval For Generic Remodulin Injection

By, Admin 13 February 2021

Alembic Pharmaceuticals Limited announced that its wholly-owned subsidiary Alembic Global Holding SA has received final approval from the US Food & Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) treprostinil injection, 20 mg/20 mL (1 mg/mL), 50 mg/20 mL (2.5 mg/mL), 100 mg/20 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL), multiple-dose vials.The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Remodulin injection, 20 mg/20 mL (1mg/mL), 50 mg/20 mL (2.5 mg/mL), 100 mg/20 mL (5 mg/mL), and 200 mg/20 mL (10mg/mL), of United Therapeutics Corp.Treprostinil injection is indicated for the treatment of pulmonary arterial to diminish symptoms associated with exercise.In patients with PAH requiring transition from epoprostenol, treprostinil injection is indicated to diminish the rate of clinical deterioration. Alembic had previously received tentative approval for this ANDA.Treprostinil injection has an estimated market size of US$ 17 million for twelve months ending December 2020, according to IQVIA.Alembic now has a total of 138 ANDA approvals (121 final approvals and 17 tentative approvals) from US FDA, including this first injectable ANDA approval.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!